Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1CNS 1

Conditions

Obesity 1Craniopharyngioma 1

Interventions

Surgical Procedures, Operative 4Magnetic Resonance Spectroscopy 3Exenatide 3tocilizumab 2Temozolomide 2Radiotherapy 2Proton Therapy 2Mental Status and Dementia Tests 2Donepezil 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2trifluridine tipiracil drug combination 1trametinib 1tozuleristide 1tovorafenib 1temsirolimus 1gallium Ga 68 dotatate 1entinostat 1dabrafenib 1cobimetinib 1carboxyamido-triazole 1binimetinib 1antineoplaston AS 2-1 1antineoplaston A10 1anlotinib 1Verteporfin 1Vemurafenib 1Transurethral Resection of Bladder 1Thalidomide 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Craniopharyngioma × CKD732 × Clear all
NCT02063295 2016-07-18

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Zafgen, Inc.

Phase 2 Completed
14 enrolled
CNSOther

Craniopharyngioma, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡